Cepheid (NASDAQ:CPHD) has earned an average rating of “Hold” from the twenty-two analysts that are covering the company. Sixteen investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $41.18.
Several equities analysts have commented on CPHD shares. Zacks Investment Research raised shares of Cepheid from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Tuesday, June 28th. Canaccord Genuity reissued a “hold” rating and issued a $32.00 target price on shares of Cepheid in a report on Wednesday, June 29th. JPMorgan Chase & Co. raised their target price on shares of Cepheid from $32.00 to $35.00 and gave the company a “neutral” rating in a report on Friday, July 29th. Jefferies Group raised their target price on shares of Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Finally, Needham & Company LLC lowered shares of Cepheid from a “buy” rating to a “hold” rating in a report on Tuesday, September 6th.
Cepheid (NASDAQ:CPHD) opened at 52.66 on Friday. Cepheid has a one year low of $25.09 and a one year high of $53.91. The firm’s market capitalization is $3.84 billion. The company has a 50-day moving average of $49.52 and a 200 day moving average of $36.23.
Cepheid (NASDAQ:CPHD) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.19. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The business had revenue of $146 million for the quarter, compared to analyst estimates of $145.82 million. During the same period last year, the firm earned ($0.06) earnings per share. Cepheid’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts anticipate that Cepheid will post $0.33 EPS for the current year.
In other news, VP Scott A. Campbell sold 746 shares of Cepheid stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the sale, the vice president now owns 10,721 shares in the company, valued at approximately $393,567.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.16% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. Societe Generale bought a new stake in Cepheid during the second quarter valued at $114,000. First Mercantile Trust Co. raised its stake in Cepheid by 6.6% in the second quarter. First Mercantile Trust Co. now owns 4,020 shares of the company’s stock valued at $124,000 after buying an additional 250 shares in the last quarter. Globeflex Capital L P bought a new stake in Cepheid during the second quarter valued at $145,000. Advisor Group Inc. bought a new stake in Cepheid during the second quarter valued at $145,000. Finally, Independent Portfolio Consultants Inc. raised its stake in Cepheid by 10.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 5,080 shares of the company’s stock valued at $156,000 after buying an additional 465 shares in the last quarter. Institutional investors own 95.27% of the company’s stock.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.